Current Trends in Effectiveness and Mechanisms of Action: A Systematic Review on the Use of GLP-1 Analogs in the Treatment of Obesity.
Vol. 5 No. 5 (2023), Systematic Review
Vol. 5 No. 5 (2023)

Current Trends in Effectiveness and Mechanisms of Action: A Systematic Review on the Use of GLP-1 Analogs in the Treatment of Obesity.

Systematic Review
https://doi.org/10.36557/2674-8169.2023v5n5p6354-6362
Published 2023-12-26
Bruna de Aquino Morais da Silva
UNIFG Guanambi
https://orcid.org/0009-0005-9780-5829
José Lucas Moura Vasconcelos
UniFG Guanambi
https://orcid.org/0009-0008-0164-5325
Leonardo Dias Azevedo
UniFG Brumado
https://orcid.org/0009-0002-4939-3637
Ana Clara Sertão Alves
UNIFG Guanambi
https://orcid.org/0009-0006-1278-1213
Anderson Almeida Marques
Universidade Federal do Oeste da Bahia - UFOB
https://orcid.org/0009-0007-6334-3827
Danielle Idelfonso Bottentuit Martins
Universidade Anhembi Morumbi - UAM
https://orcid.org/0009-0006-7351-3837
Edvard José dos Santos Neto
FIP Guanambi
https://orcid.org/0000-0002-9149-1321
Emili Mariane Machado Gonçalves
UNIFG Guanambi
https://orcid.org/0009-0003-9468-7906
Géssica Lima Ribeiro
UNIFG Guanambi
https://orcid.org/0009-0000-5632-7836
Julia de Souza Ferreira dos Santos
Universidade Anhembi Morumbi - UAM
https://orcid.org/0009-0004-2838-5667
Marcio Ryan Araújo de Novaes
UNIFG Guanambi
https://orcid.org/0009-0001-1709-5443
Rafaela Magalhães Gondim
UNIFG Guanambi
https://orcid.org/0009-0007-7807-1684
Rafaella Cançado Constantino de Giácomo
UniBH
https://orcid.org/0009-0009-3287-7716
Roberta Helena Marques de Oliveira
Universidade Federal do Oeste da Bahia - UFOB
https://orcid.org/0009-0000-6694-6219
Thaís da Silva Torres
UNIFG - Brumado
https://orcid.org/0009-0007-6684-5267
Vanessa Avelar Alcântara Melo
Anhembi Morumbi - UAM
https://orcid.org/0009-0003-8232-5414
Vinycius Victor Ferreira Venuto
FIP Guanambi
https://orcid.org/0009-0002-1759-1882
PDF (Português (Brasil))

Keywords

Obesidade
Agonistas do GLP-1
Tratamento

How to Cite

Silva, B. de A. M. da, Moura Vasconcelos, J. L., Azevedo, L. D., Alves, A. C. S., Marques, A. A., Martins, D. I. B., Santos Neto, E. J. dos, Gonçalves, E. M. M., Ribeiro, G. L., Santos, J. de S. F. dos, Novaes, M. R. A. de, Gondim, R. M., Giácomo, R. C. C. de, Oliveira, R. H. M. de, Torres, T. da S., Melo, V. A. A., & Venuto, V. V. F. (2023). Current Trends in Effectiveness and Mechanisms of Action: A Systematic Review on the Use of GLP-1 Analogs in the Treatment of Obesity. Brazilian Journal of Implantology and Health Sciences, 5(5), 6354–6362. https://doi.org/10.36557/2674-8169.2023v5n5p6354-6362
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

This work presents a systematic review on current trends in the effectiveness and mechanisms of action of GLP-1 analogs in the treatment of obesity. The introduction highlights the growing prevalence of obesity as a global public health challenge, positioning GLP-1 analogs as a promising approach. The methodology describes the formulation of the research question, study selection criteria, data extraction, and the analysis of study quality. The results emphasize the efficacy of these analogs in weight reduction, explore the neurobiological mechanisms involved, and demonstrate improvements in obesity-related comorbidities. The conclusion underscores the consistency of the reviewed evidence and the need for further research to optimize personalized therapeutic approaches.

https://doi.org/10.36557/2674-8169.2023v5n5p6354-6362
PDF (Português (Brasil))

References

Adams, S. H., Lei, C., Jodka, C. M., Nikoulina, S. E., Hoyt, J. A., Gedulin, B., ... & Ruddy, M. (2018). Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, reduces body weight and food intake in obese rodents and primates. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 295(3), R1078-R1086.

Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., ... & Rössner, S. (2016). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity, 40(1), 28-35.

Astrup, A., Caterson, I., Carraro, R., Finer, N., Geiselman, P., Rissanen, A., ... & Group, R. I. S. (2009). Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity, 33(2), 160-168.

Davies, M., Pieber, T. R., Hartoft-Nielsen, M. L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2015). Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA, 314(21), 2224-2234.

Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., ... & Camilleri, M. (2016). Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA, 315(22), 2424-2434

Meier, J. J., & Nauck, M. A. (2018). Incretin-based therapies: where will we be 50 years from now? Diabetologia, 61(10), 2254-2259.

Oliveira, M. C., Zambon, M. P., Rodrigues, M. F., Mori, R. C., Sibio, M. T., Pinhel, M. A., ... & Oliveira, E. P. (2021). Liraglutide and lipid profile in patients with type 2 diabetes and obesity: a real-world evidence study. Diabetology & Metabolic Syndrome, 13(1), 1-9.

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Liraglutide 3.0 mg for the Treatment of Obesity Study Group. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.

Smith, E. P., An, Z., Wagner, C., Lewis, A. G., Cohen, E. B., Li, B., ... & Seeley, R. J. (2019). The role of central GLP-1 in mediating the effects of the bariatric surgery on body weight and glucose homeostasis. NeuroImage, 192, 100-108.

Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., ... & Group, E. S. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443-1451.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Bruna de Aquino Morais da Silva, José Lucas Moura Vasconcelos, Leonardo Dias Azevedo, Ana Clara Sertão Alves, Anderson Almeida Marques, Danielle Idelfonso Bottentuit Martins, Edvard José dos Santos Neto, Emili Mariane Machado Gonçalves, Géssica Lima Ribeiro, Julia de Souza Ferreira dos Santos, Marcio Ryan Araújo de Novaes, Rafaela Magalhães Gondim, Rafaella Cançado Constantino de Giácomo, Roberta Helena Marques de Oliveira, Thaís da Silva Torres, Vanessa Avelar Alcântara Melo, Vinycius Victor Ferreira Venuto